AAP
NGNE icon

Arax Advisory Partners’s Neurogene NGNE Stock Holding History

Arax Advisory Partners’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$28.5K Buy
906
+892
+6,371% +$24.6K ﹤0.01% 3709
2026
Q1 		$282 Buy
14
+12
+600% +$232 ﹤0.01% 3499
2025
Q4 		$41 Sell
2
-14
-88% -$348 ﹤0.01% 3953
2025
Q3 		$277 Buy
+16
New +$321 ﹤0.01% 3424

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Arax Advisory Partners's NGNE Position: Q2 2026 in Review

Arax Advisory Partners increased its Neurogene (NGNE) stake by 6,371% in Q2 2026, buying an estimated $24.6K and bringing the position to 906 shares worth $28.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3709.

Arax Advisory Partners first reported a position in NGNE in Q3 2025 and has held it in 4 quarters since. 112 funds tracked by Wall St. Rank hold NGNE as of Q2 2026.

  • Arax Advisory Partners held 906 shares of Neurogene worth $28.5K as of Q2 2026.
  • Arax Advisory Partners bought 892 Neurogene shares in Q2 2026, an estimated $24.6K.
  • Neurogene made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #3709 holding.
  • Arax Advisory Partners first reported a position in Neurogene in Q3 2025 and has held it in 4 quarters since.
  • 112 funds tracked by Wall St. Rank held Neurogene as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.